STOCK TITAN

Roivant Sciences CFO Richard Pulik sells 125,000 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Roivant Sciences Ltd. CFO Richard Pulik exercised options for 125,000 common shares on November 10 and 127,365 shares on November 11, each at $3.85 per share. He sold 125,000 shares at $41.20 per share on November 10. On November 11, he sold 45,195 shares at a weighted average price of $41.47, 82,170 at $42.03 and 47,635 at $41.89. The option award was fully vested.

Insider Pulik Richard
Role CFO
Sold 300,000 shs ($12.47M)
Approx. gross sale proceeds $12.47M
Approx. exercise cost $972K
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) F5 127,365 $0.00 $0.00
Exercise Common Shares 127,365 $3.85 $490K
Sale Common Shares F2 45,195 $41.47 $1.87M
Sale Common Shares F3 82,170 $42.03 $3.45M
Sale Common Shares F4 47,635 $41.89 $2.00M
Exercise Stock Option (Right to Buy) F5 125,000 $0.00 $0.00
Exercise Common Shares 125,000 $3.85 $481K
Sale Common Shares F1 125,000 $41.20 $5.15M
Holdings After Transaction: Stock Option (Right to Buy) — 487,635 options (Direct); Common Shares — 222,046 shares (Direct)
Footnotes (5)
  1. F1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.16 to $41.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
  2. F2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.88 to $41.83, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
  3. F3. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.94 to $42.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
  4. F4. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.79 to $42.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
  5. F5. Reflects an award of stock options to purchase Common Shares that is fully vested.
Options exercised 125,000 shares November 10, 2026; exercise price $3.85 per share
Options exercised 127,365 shares November 11, 2026; exercise price $3.85 per share
Exercise price $3.85 per share Options exercised on November 10 and November 11, 2026
Shares sold 125,000 shares at $41.20 per share November 10, 2026
Shares sold 45,195 shares at weighted average price of $41.47 per share November 11, 2026
Shares sold 82,170 shares at weighted average price of $42.03 per share November 11, 2026
Shares sold 47,635 shares at weighted average price of $41.89 per share November 11, 2026
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy)"
weighted average price financial
"The price reported in column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
fully vested financial
"stock options to purchase Common Shares that is fully vested"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ROIV shares did CFO Richard Pulik sell, and at what prices?

Richard Pulik sold 125,000 shares on November 10 at $41.20 per share; on November 11, he sold 45,195 shares at a weighted average price of $41.47, 82,170 at $42.03 and 47,635 at $41.89. The November 11 weighted average prices reflected sales within ranges of $40.88–$41.83, $41.94–$42.14 and $41.79–$42.14, respectively. No Rule 10b5-1 plan is reported.

How many ROIV options did Richard Pulik exercise, and at what price?

He exercised options for 125,000 shares on November 10 and 127,365 shares on November 11, at $3.85 per share. The award was fully vested.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Pulik Richard

(Last)(First)(Middle)
C/O ROIVANT SCIENCES LTD.
7TH FLOOR, 50 BROADWAY

(Street)
LONDONSW1H 0DB

(City)(State)(Zip)

UNITED KINGDOM

(Country)
2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CFO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/10/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Shares11/10/2026M125,000A$3.85394,681D
Common Shares11/10/2026S125,000D$41.2(1)269,681D
Common Shares11/11/2026M127,365A$3.85397,046D
Common Shares11/11/2026S45,195D$41.47(2)351,851D
Common Shares11/11/2026S82,170D$42.03(3)269,681D
Common Shares11/11/2026S47,635D$41.89(4)222,046D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$3.8511/10/2026M125,000 (5)04/19/2032Common Stock125,000$0615,000D
Stock Option (Right to Buy)$3.8511/11/2026M127,365 (5)04/19/2032Common Stock127,365$0487,635D
Explanation of Responses:
1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.16 to $41.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.88 to $41.83, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
3. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.94 to $42.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
4. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.79 to $42.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
5. Reflects an award of stock options to purchase Common Shares that is fully vested.
Remarks:
By: /s/ Sam Kaplan, as Attorney-in-Fact for Richard Pulik11/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading